Tools
Stock profile

INSMED Inc (INSM)

INSM · Latest close $119.80 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$119.80
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
1 / 3
vs previous quarter
Trimmed / exited
2
vs previous quarter

INSMED Inc (INSM) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 3 funds adding, and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $3.1M sold). 0 members of Congress reported 0 purchases vs 1 sale. Latest close $119.80 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Sep 9, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-3.1M
Congress
0 buys vs 1 sale
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Baker Bros. Advisors · RTW Investments · Paradigm Biocapital Advisors — 6 tracked funds hold INSM. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($3.1M). Insider trading 0 members of Congress reported buying (0 purchases vs 1 sale). Politician trading

Often held alongside

ERASCA INC (ERAS) · Wave Life Sciences, Inc. (WVE) · BELITE BIO, INC (BLTE) · REPLIGEN CORP (RGEN) · SPYRE THERAPEUTICS INC (SYRE) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Baker Bros. Advisors4.70%8,796,111ADDED (+18.5%) Q3 filed Nov 16
RTW Investments4.41%4,842,880HELD Q3 filed Nov 16
Paradigm Biocapital Advisors2.65%1,325,977ADDED (+5.7%) Q3 filed Nov 16
Maverick Capital2.03%2,150,762NEW Q3 filed Nov 16
Samlyn Capital1.27%732,568ADDED (+75.6%) Q3 filed Nov 16
Thornburg Investment Management0.02%18,413TRIMMED (-52.0%) Q3 filed Nov 13
Axiom Investors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +13.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

211.4158.952024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding666 of 8,857 filers
Long-only filers among them663
Change vs 2026 Q1+3 net · 604 entered · 601 exited
Shares reported, all filers223,141,214
Reported value, all filers$23.5B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$606.4M
Net income · FY2025$-1.3B
Total assets · FY2025$2.3B
Shares outstanding219,380,309
Market cap (at latest close)$26.3B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Oct 23, 2026.

Short interest

Shares short · Oct 15, 202613,477,593
Share of shares outstanding6.14%
Days to cover4.13

Shares short at recent settlements — Jul 31, 2026: 11.4M · Aug 14, 2026: 10.9M · Aug 31, 2026: 11.4M · Sep 15, 2026: 10.8M · Sep 30, 2026: 13.8M · Oct 15, 2026: 13.5M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Oct 23, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Oct 23, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($3.1M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Sep 9, 2026Brennan David RSell25,000$124.00$3.1MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 10, 2026Brennan David RDirector25,000$3.1MSep 9, 2026SEC filing
Aug 17, 2026MELVIN SHAROKYDirector5,000$637.6KAug 17, 2026SEC filing
Aug 10, 2026Roger AdsettOfficer239,850$32.0MAug 10, 2026SEC filing
Aug 6, 2026Martina FlammerOfficer27,173$3.5MAug 6, 2026SEC filing
Jul 23, 2026William LewisOfficer10,700$1.1MJul 23, 2026SEC filing
Jul 9, 2026William LewisOfficer10,699$1.3MJul 9, 2026SEC filing
Jul 6, 2026Martina FlammerOfficer12,302$1.4MJul 6, 2026SEC filing
Jun 25, 2026William LewisOfficer21,398$2.2MJun 25, 2026SEC filing
Jun 22, 2026Michael SmithOfficer1,806$173.0KJun 22, 2026SEC filing
Jun 8, 2026William LewisOfficer6,515$612.6KJun 8, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026Darwin Global Management, Ltd.SC 13G/A6,431,1633.0%Jun 30, 2026SEC filing
Aug 6, 2026FMR LLCSC 13G/A16,127,583.087.4%Jun 30, 2026SEC filing
Jul 22, 2026JPMORGAN CHASE & CO.SC 13G/A10,365,6224.7%Jun 30, 2026SEC filing
May 15, 2026Darwin Global Management, Ltd.SC 13G/A16,805,1847.8%Mar 31, 2026SEC filing
May 6, 2026FMR LLCSC 13G13,145,166.526.1%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G11,514,8935.3%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A14,121,4456.6%Dec 31, 2025SEC filing
Nov 14, 2025Darwin Global Management, Ltd.SC 13G/A20,457,4459.7%Sep 30, 2025SEC filing
Nov 14, 2025T. Rowe Price Associates, Inc.SC 13G/A6,932,0093.3%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

0 members of Congress reported buying (0 purchases vs 1 sale).

Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.

Recent activity by member

MemberChamberPartyBuysSellsLatestAmount range
Gottheimer, JoshHouseD01Jun 10, 2026$1,001 - $15,000

Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 36 Lobbying Disclosure Act filings named this company as client, 2005–2026; most common issues: Pharmacy (17), Health Issues (16), Medicare/Medicaid (6).

Federal contracts: $124.0K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$15.4K
FY2022$0
FY2023$53.6K
FY2024$-26.8K
FY2025$111.2K
FY2026$-29.4K

Largest awards collected

Award IDAgencyAmountStart
36C24526N0641Department of Veterans Affairs$31.2KJun 10, 2026
36C26223F0566Department of Veterans Affairs$26.8KJul 13, 2023
36C24221N0228Department of Veterans Affairs$15.4KOct 9, 2020
36C24525N0383Department of Veterans Affairs$10.1KFeb 13, 2025
36C26025F0190Department of Veterans Affairs$10.1KMar 21, 2025

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Growth — Latest revenue: $606.4M · 5-yr revenue CAGR: 29.8% · Straight growth years: 8

· Distress Risk (Altman Z″) — Z″-Score: -7.47 · Working capital / assets: 0.59 · Retained earnings / assets: -2.49 · EBIT / assets: -0.55 · Equity / liabilities: 0.48

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2022 Q4, ranked #38 of 50.

Also held by the tracked funds that hold INSM — ranked by lift, the co-holding pattern described in Methodology: ERASCA INC (ERAS) · Wave Life Sciences, Inc. (WVE) · BELITE BIO, INC (BLTE) · REPLIGEN CORP (RGEN) · SPYRE THERAPEUTICS INC (SYRE) · TANGO THERAPEUTICS INC (TNGX) · CYTOKINETICS INC (CYTK) · Dianthus Therapeutics, Inc. /DE/ (DNTH).

Filings audit: every filing lens on INSMED Inc (INSM), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Oct 29, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Oct 20, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 5, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ERASCA INC (ERAS) · Filings audit: every filing lens on INSMED Inc (INSM), scored · Practice timing on INSM

One email a week: the week’s new filings and research. Subscribe free

← INSG  ·  INSP →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.